2C-CPe, also known as 4-cyclopentyl-2,5-dimethoxyphenethylamine, is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024. It is a moderately potent agonist at the serotonin receptor 5-HT<sub>2A</sub> in vitro, with a binding affinity (K<sub>i</sub>) of 134 nM, slightly weaker than the related cyclopropyl compound 2C-CP. It is not known to have been tested in humans or animals. It is a controlled substance in Canada under phenethylamine blanket-ban language.